HHS plan to be publicly released in coming weeks, White House official says. Meanwhile the US House passed a resolution clearing the way for consideration of a second infrastructure package that could include major drug pricing reforms such as Medicare price negotiation as cost offsets.
The US Health and Human Services Department has forwarded a plan for executive actions on drug pricing reform to the White House. But the Administration is withholding details of the plan at present, presumably to give leaders in Congress time to try moving legislation on Democratic priorities like authorizing government price negotiation in Medicare.
Biden directed HHS Secretary Xavier Becerra to develop a “comprehensive” plan on drug pricing reform within 45 days in an...
Doctors are increasingly falling victim to financial scams due to their high incomes, busy schedules, and trust in professional networks. Recognizing the tactics scammers use and the reasons behind physicians’ susceptibility is essential for protecting medical professionals.
Senate HELP Committee chair Sanders trying to broker a deal between Novo Nordisk and the major pharmacy benefit managers that will lead to lower list prices.
Alternatives to the top pharmacy benefits managers argue health plan-PBM integration is leading to anti-competitive tactics that make it impossible for some employers to switch PBMs.
An effort to change the US Food and Drug Administration’s conclusion that its obesity treatment candidate retatrutide is a drug and not a biologic could give the product more time with unrestricted pricing in Medicare, among other benefits.
Pharmacy benefit manager sues Federal Trade Commission claiming chair Khan has orchestrated a campaign against PBMs that is not based in fact.
Alternatives to the top pharmacy benefits managers argue health plan-PBM integration is leading to anti-competitive tactics that make it impossible for some employers to switch PBMs.
The UK regulator approved 16 medicines containing a new active substance in the first half of this year, while the European Commission issued marketing authorizations for 20 NAS-containing drugs.
